drugset / Trial / NCT07109531
ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to compare the safety and efficacy of ASKC202 combined with Limertinib Versus platinum-based chemotherapy in locally advanced or metastatic NSCLC With MET Amplification/Overexpression after disease progression on EGFR tyrosine kinase inhibitor.
Timeline
- Start
- 2025-08-31
- Primary completion
- 2027-10-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASKC202 | Unknown | — | Oral |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Cisplatin | Other / unclassified | — | — |
| Subject | Limertinib | Small molecule | — | Oral |
| Comparator | Pemetrexed | Small molecule | — | — |
Indications
No indication recorded.